David Critchley

1.5k citations

24 papers · 1.2k indexed · h-index 16

Impact in

Cellular and Molecular Neuroscience top 5%
- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
Psychiatry and Mental health top 5%
- Epilepsy research and treatment

Papers in

Pharmacology 5
- Cannabis and Cannabinoid Research 6
- Pharmacogenetics and Drug Metabolism 4
Psychiatry and Mental health 8
- Epilepsy research and treatment 8

Co-authors: Christine Beedham David J. Rance Eliane Fuseau Colin T. Dourish James C. Cloyd Emilio Perucca Vicki C. Middlefell Anne‐Marie Laporte
Journals: Investigational New Drugs (3 papers)Epilepsia (3 papers)European Journal of Pharmacology (2 papers)European Journal of Paediatric Neurology (2 papers)Behavioural Brain Research (1 paper)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

David Critchley

24 papers receiving 1.2k citations

Peers

Countries citing papers authored by David Critchley

Since Specialization

Citations

This map shows the geographic impact of David Critchley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Critchley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Critchley more than expected).

Fields of papers citing papers by David Critchley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Critchley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Critchley. The network helps show where David Critchley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Critchley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Critchley Line = papers co-authored together David Critchley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pharmacokinetic Drug‐Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial Clinical Pharmacology in Drug Development ·Elizabeth Wilk, Joris Berwaerts, David Critchley, A. D. Hatti, Cuiping Chen, Jinshuang Liu, Bola Tayo	2023	12
2	A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects Clinical Pharmacology in Drug Development ·Jinshuang Liu, Bola Tayo, David Critchley	2021	21
3	A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy CNS Drugs ·Elinor Ben‐Menachem, Boudewijn Gunning, Carmen Cabrera, Kevan VanLandingham, Julie C. Crockett, David Critchley, Elizabeth Wilk, Bola Tayo, Gilmour Morrison, Manuel Toledo	2020	37
4	Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison Investigational New Drugs ·Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, Robert S. Jansen, Hilde Rosing, Hitoshi Mizuo, Luís Miguel P. de Sousa, David Critchley, Robert Shumaker, Jan H.M. Schellens, Jos H. Beijnen	2016	13
5	Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study European Journal of Paediatric Neurology ·Alexis Arzimanoglou, José Alexandre Ferreira, Andrew Satlin, LV Qing-wei, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani	2016	29
6	Investigation of the Metabolism of Rufinamide and Its Interaction with Valproate Drug Metabolism Letters ·Eric T. Williams, Jennifer Lund, Abdullah Abualadas, Y. Nancy Wong, Tsutomu Yoshimura, David Critchley, Milind M. Narurkar	2011	21
7	Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects Clinical Therapeutics ·David Critchley, Jagadeesh Aluri, Peter D. W. Boyd, Miles Elliott, Milind M. Narurkar, Kostas Apostolakis, Francesco Bibbiani	2011	8
8	Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation Journal of Pharmacokinetics and Pharmacodynamics ·Bekpo‘lat Umurqulov, Eliane Fuseau, David Critchley	2010	11
9	Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820 Investigational New Drugs ·Ron J. Keizer, Miren Zamacona, Mendel Jansen, David Critchley, J. Wanders, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema	2008	21
10	Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy Epilepsia ·Emilio Perucca, James C. Cloyd, David Critchley, Eliane Fuseau	2008	168
11	Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol Investigational New Drugs ·H.J.G.D. van den Bongard, Rolf W. Sparidans, David Critchley, Jos H. Beijnen, Jan H.M. Schellens	2004	4
12	Substrate Specificity of Human Liver Aldehyde Oxidase toward Substituted Quinazolines and Phthalazines: A Comparison with Hepatic Enzyme from Guinea Pig, Rabbit, and Baboon Archives of Biochemistry and Biophysics ·Christine Beedham, David Critchley, David J. Rance	1995	74
13	Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist Behavioural Brain Research ·Allan Fletcher, Leann Ness, David J. Bill, Geraldine Brown, Ian A. Cliffe, A Grizic, Deborah E. Jones, David Taylor-Robinson, Kelly J. Stanhope, David Critchley, S. Siggia, Vicki C. Middlefell, Laurence Lanfumey, Renato Corradetti, Anne‐Marie Laporte, H. Gozlan, Michel Hamon, Colin T. Dourish	1995	473
14	Comparisons between the effects of 5-HT and dl-fenfluramine on food intake and gastric emptying in the rat Pharmacology Biochemistry and Behavior ·David Critchley, Colin T. Dourish, Steven J. Cooper, John Francis	1995	19
15	Biotransformation of carbazeran in guinea pig: Effect of hydralazine pretreatment Xenobiotica ·David Critchley, David J. Rance, Christine Beedham	1994	21
16	Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats European Journal of Pharmacology ·David Critchley, Vicki C. Middlefell, Christopher Liddle, Ayşegül Kuş, Colin T. Dourish	1994	14
17	Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635 European Journal of Pharmacology ·David Critchley, S. Siggia, Vicki C. Middlefell, Colin T. Dourish	1994	35
18	Subcellular localisation of guinea pig hepatic molybdenum hydroxylases Biochemical and Biophysical Research Communications ·David Critchley, David J. Rance, Christine Beedham	1992	20
19	1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases Biochemical Pharmacology ·Christine Beedham, Sally Bruce, David Critchley, David J. Rance	1990	33
20	Species variation in hepatic aldehyde oxidase activity European Journal of Drug Metabolism and Pharmacokinetics ·Christine Beedham, Sally Bruce, David Critchley, J. Purvis, David J. Rance	1987	85

About David Critchley

David Critchley is a scholar working on Pharmacology, Pharmacology, Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Clinical Biochemistry, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include Pharmacological Effects and Toxicity Studies (9 papers), Epilepsy research and treatment (8 papers), Cannabis and Cannabinoid Research (6 papers), Neurotransmitter Receptor Influence on Behavior (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Alcohol Consumption and Health Effects (3 papers), Analytical Chemistry and Chromatography (2 papers) and Metabolism and Genetic Disorders (2 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (531 citations), Psychiatry and Mental health (274 citations), Pharmacology (155 citations), Pharmacology (267 citations) and Behavioral Neuroscience (41 citations). David Critchley has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Christine Beedham, David J. Rance, Eliane Fuseau, Colin T. Dourish, James C. Cloyd, Emilio Perucca, Vicki C. Middlefell, Anne‐Marie Laporte, Michel Hamon and David J. Bill. Their work appears in journals such as Investigational New Drugs, Epilepsia, European Journal of Pharmacology, European Journal of Paediatric Neurology and Behavioural Brain Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact